Terms: = Endocrine gland cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
10 results:
1. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.
Marchocki Z; Tone A; Virtanen C; de Borja R; Clarke B; Brown T; May T
J Ovarian Res; 2022 May; 15(1):50. PubMed ID: 35501919
[TBL] [Abstract] [Full Text] [Related]
2. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Green ML; Ma SC; Goble S; Giordano H; Maloney L; Simmons AD; Beltman J; Harding TC; Xiao JJ
Cancer Chemother Pharmacol; 2022 May; 89(5):671-682. PubMed ID: 35397664
[TBL] [Abstract] [Full Text] [Related]
3. Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.
Trousil S; Lee P; Edwards RJ; Maslen L; Lozan-Kuehne JP; Ramaswami R; Aboagye EO; Clarke S; Liddle C; Sharma R
Br J Pharmacol; 2019 Sep; 176(18):3712-3722. PubMed ID: 31236938
[TBL] [Abstract] [Full Text] [Related]
4. Genetic polymorphism of cyp2d6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract] [Full Text] [Related]
5. cyp2d6 genetic polymorphisms are associated with susceptibility to pituitary tumors.
Gomes L; Lemos MC; Paiva I; Ribeiro C; Carvalheiro M; Regateiro FJ
Acta Med Port; 2005; 18(5):339-43. PubMed ID: 16611538
[TBL] [Abstract] [Full Text] [Related]
6. Refinement of an ovarian cancer tumour suppressor gene locus on chromosome arm 22q and mutation analysis of cyp2d6, SREBP2 and NAGA.
Bryan EJ; Thomas NA; Palmer K; Dawson E; Englefield P; Campbell IG
Int J Cancer; 2000 Sep; 87(6):798-802. PubMed ID: 10956388
[TBL] [Abstract] [Full Text] [Related]
7. Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer.
Lee HC; Yoon YB; Kim CY
Korean J Intern Med; 1997 Jun; 12(2):128-36. PubMed ID: 9439147
[TBL] [Abstract] [Full Text] [Related]
8. Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression.
Sarhanis P; Redman C; Perrett C; Brannigan K; Clayton RN; Hand P; Musgrove C; Suarez V; Jones P; Fryer AA; Farrell WE; Strange RC
Br J Cancer; 1996 Dec; 74(11):1757-61. PubMed ID: 8956789
[TBL] [Abstract] [Full Text] [Related]
9. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and cyp2d, on chromosome 22q.
Bryan EJ; Watson RH; Davis M; Hitchcock A; Foulkes WD; Campbell IG
Cancer Res; 1996 Feb; 56(4):719-21. PubMed ID: 8631002
[TBL] [Abstract] [Full Text] [Related]
10. GSTM1 and cyp2d6 genotype frequencies in patients with pituitary tumours: effects on P53, ras and gsp.
Perrett CW; Clayton RN; Pistorello M; Boscaro M; Scanarini M; Bates AS; Buckley N; Jones P; Fryer AA; Gilford J
Carcinogenesis; 1995 Jul; 16(7):1643-5. PubMed ID: 7614700
[TBL] [Abstract] [Full Text] [Related]
